Regulatory clearances achieved that enable integration of the plato™ platform into Fabry FAB-201 and Gaucher GAU-201 clinical trials in the second half of 2019 IND for AVR-RD-01 for the treatment of Fabry disease cleared by the FDA ; AVROBIO plans to open U.S.
The plato™ platform represents a significant advance towards a commercial-stage gene therapy solution designed to treat thousands of patients AVROBIO to incorporate U.S. clinical sites into its ongoing global FAB-201 Phase 2 clinical trial in Fabry disease CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 26, 2019-- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the participation of its senior management in sessions at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).